Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 391Carboplatin 345pembrolizumab 332Gemcitabine 332Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 288Bevacizumab 254Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 191fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 153Irinotecan 149Leucovorin 145Etoposide 144Cytarabine 134Cetuximab 131fludarabine phosphate 129Bortezomib 129Lenalidomide 126Erlotinib Hydrochloride 121Filgrastim 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × remetinostat × Clear all
NCT03875859 2021-05-20

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Stanford University

Phase 2 Terminated
4 enrolled 9 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡